The companies have entered into a manufacturing agreement to supply leronlimab, an investigational new drug currently being used in clinical trial protocols for COVID-19.
On May 5, 2020, Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a contract development and manufacturing organization, announced that it has entered into a manufacturing services agreement with CytoDyn, a late-stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), which is currently being used in clinical trial protocols for mild-to-moderately ill and severely ill COVID-19 patients.
Leronlimab is a novel CCR5 antagonist with the potential for multiple therapeutic indications. It has been and is currently being administered to COVID-19 patients at New York City area hospitals as part of an emergency investigational new drug (EIND), granted by FDA as part of Phase I, Phase II, and Phase IIb/III clinical trials. CytoDyn is currently enrolling patients in two placebo-controlled randomized clinical trials for Phase II and Phase IIb/III.
"We are very excited to support CytoDyn's efforts to utilize this promising antibody therapeutic in the fight against COVID-19," said Kristin DeFife, PhD, senior vice-president of Operations and site head at Ajinomoto Bio-Pharma Services, in a company press release.
"We are extremely pleased to already have been collaborating with Aji Bio-Pharma for the production of leronlimab for other therapeutic indications, allowing us to quickly provide this therapeutic to COVID-19 patients in clinical trials," said Nader Pourhassan, PhD, president and CEO of CytoDyn, in the press release. "Aji Bio-Pharma's drug product experience, infrastructure, and strong regulatory track record were important to this partnership and in the timely supply of this therapeutic."
Source: Ajinomoto Bio-Pharma Services
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.